Binding of this drug to the PD-1 receptor leads to a conformational change in PD-1 that prevents it from binding to PD-L1, thus allowing the continuous activation and proliferation of T cells and promoting the elimination of tumour cells [115,116]. The gene discussed is CD274; the disease is neoplasm.